The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > COLUMN
COLUMN
-
Current Topics of New Drug Development and Marketing in the World: 2
July 10, 2015
-
Current Topics of New Drug Development and Marketing in the World: 1
July 9, 2015
-
The Mastery of Recruitment
June 26, 2015
-
“Every Search Is Won Before It’s Ever Fought”: Sun Tzu
May 22, 2015
-
The Truth about Recruiters
April 21, 2015
-
When Interviewing, Share the Love
March 27, 2015
-
Sales Experience for Marketers Deceasing in Japan’s Pharma Industry
February 20, 2015
-
Eliminating Bias from the Interview Process
January 23, 2015
-
Loss Aversion: Why Candidates Reject Offers
December 26, 2014
-
What You Don’t Know About Communication Can Hurt You
November 28, 2014
-
3 Reasons Why KOL Management Is No Longer Enough
October 22, 2014
-
Successful People Have the Best Information
September 24, 2014
-
Is Your Body Language Louder than Your Speech?
August 25, 2014
-
Taking Pride in Small Things Makes Big Things Possible
July 25, 2014
-
It’s Moments Like These
June 27, 2014
-
How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
-
Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
-
Emerging Immunotherapy of Cancer: 2
April 11, 2014
-
Emerging Immunotherapy of Cancer: 1
April 10, 2014
-
Sun Tzu and the Art of Interviewing
March 18, 2014
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…